PT Kimia Farma Tbk Class B KAEF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 450.05
- Price/Sales
- 0.46
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
PT Kimia Farma Tbk is an Indonesia based company engaged in the production and distribution of healthcare products. It operates through the following segments: Manufacture, Distribution, Retail, and Others. The company provides its products in three categories including Ethical, Generic and others. Some of its product offerings include Topgesic, Protofen, Neurodial, Omeprazole, Antalgin, Pethidine, Salicylfresh and Doveri. It generates maximum revenue from the retail segment.
- Sector
- Healthcare
- Industry
- Medical Distribution
- Stock Style Box
- Small Value
- Total Number of Employees
- 11,560
- Website
- https://www.kimiafarma.co.id
Comparables
Valuation
|
Metric
|
KAEF
|
NICL
|
MPRO
|
|---|---|---|---|
Price/Earnings (Normalized) | 450.05 | — | — |
Price/Book Value | 0.59 | 2.07 | 17.71 |
Price/Sales | 0.46 | 1.59 | 2,841.42 |
Price/Cash Flow | — | — | — |
Price/Earnings
KAEF
NICL
MPRO
Financial Strength
|
Metric
|
KAEF
|
NICL
|
MPRO
|
|---|---|---|---|
Quick Ratio | 0.48 | 1.60 | 0.03 |
Current Ratio | 0.97 | 5.67 | 0.04 |
Interest Coverage | 1.19 | — | −0.76 |
Quick Ratio
KAEF
NICL
MPRO
Profitability
|
Metric
|
KAEF
|
NICL
|
MPRO
|
|---|---|---|---|
Return on Assets (Normalized) | −0.20% | −2.29% | −2.31% |
Return on Equity (Normalized) | −0.53% | −2.65% | −4.32% |
Return on Invested Capital (Normalized) | 2.16% | −2.73% | −1.11% |
Return on Assets
KAEF
NICL
MPRO
Medical Distribution Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MCK
| McKesson Corp | Ljtqkptzn | Tbhzlhb | $73.4 Bil | |
COR
| Cencora Inc | Bwwsfqt | Bszdd | $44.1 Bil | |
CAH
| Cardinal Health Inc | Pqnpcqst | Vnsgvg | $24.0 Bil | |
SHTDF
| Sinopharm Group Co Ltd | — | Pwhlyy | $8.8 Bil | |
SHTDY
| Sinopharm Group Co Ltd ADR | — | Nrhkzr | $8.8 Bil | |
SHPMF
| Shanghai Pharmaceuticals Holding Co Ltd Class H | — | Htxvy | $8.7 Bil | |
SHPMY
| Shanghai Pharmaceuticals Holding Co Ltd ADR repr Class H | — | Snbkf | $8.6 Bil | |
AMFPF
| Amplifon SpA Az nom Post Frazionamento | — | Qxgpl | $8.5 Bil | |
MAHLY
| Medipal Holdings Corp ADR | — | Vcmvn | $3.1 Bil | |
MEPDF
| Medipal Holdings Corp | — | Zdl | $3.0 Bil |